Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

Scientists develop panel of recombinant human snake venom antibodies

IONTAS logo 7.4.18UK-headquartered IONTAS Limited, a company specialising in the discovery and optimisation of fully human antibodies, has published a research paper in Nature Communications in collaboration with the Technical University of Denmark and the Instituto Clodomiro Picado of the University of Costa Rica describing the development of a panel of human antibodies that neutralise elements of black mamba snake toxin in an in-vivo model. Snakebite envenoming has recently been introduced on the World Health Organization’s list of neglected tropical diseases due to its high disease burden.

The proof of concept research described in Nature Communications identifies key components in the black mamba’s venom that contribute to venom toxicity, which include dendrotoxins. Human antibodies were generated to these dendrotoxins using IONTAS Phage Display Technology and mixtures of IgG-formatted human antibodies were then shown to protect mice from dendrotoxin-mediated neurotoxicity in vivo.

For further information about IONTAS Limited visit www.iontas.co.uk

Last modified onWednesday, 14 November 2018 09:43